Skip to content


  • Oral presentation
  • Open Access

Pediatric scoliosis predictive blood tests: progress and challenges for clinicians

  • Alain Moreau1,
  • Marie-Yvonne Akoume1,
  • Anita Franco1,
  • Isabelle Turgeon1,
  • Maryam Taheri1,
  • Ginette Lacroix1,
  • Ginette Larouche1,
  • BenoÎt St-Jacques1,
  • Da Shan Wang1,
  • Hubert Labelle1,
  • BenoÎt Poitras1,
  • Charles-Hilaire Rivard1,
  • Guy Grimard1,
  • Stefan Parent1 and
  • Jean A Ouellet1
Scoliosis20105(Suppl 1):O3

Published: 10 September 2010


MelatoninSpinal DeformityRobotic PlatformAsymptomatic ChildScoliosis Patient


There are great needs for innovative pharmacotherapies in combination with clinical tests to identify asymptomatic children at risk of developing scoliosis and symptomatic ones to predict who may be at risk of scoliotic curve progression. Early detection of scoliosis is critical to broaden the range of treatment options and increases effectiveness. Currently, there are no FDA cleared “pre-symptomatic” diagnostic tests available for assessing scoliosis in paediatric patients. We have developed a cell-based screening assay for the early diagnosing of presymptomatic subjects and a biochemical blood test for asymptomatic individuals and patients at different disease stage.


Peripheral blood samples for AIS patients, asymptomatic children and control subjects were collected in blood collection tubes containing EDTA and then centrifuged on a Ficoll-Plaque solution to obtain peripheral blood mononuclear cells (PBMCs) and plasma. Gi-coupled receptor signal transduction was measured by cellular dielectric spectroscopy (CDS) in presence of varying concentration of melatonin or other ligands. Plasma concentrations of OPN and sCD44 were measured by ELISA methods adapted to be performed on a robotic platform.


In a cross-sectional clinical study, we have shown that mean plasma OPN levels were significantly increased in AIS patients (n=320) and correlated with disease severity with average values of 743±326 and 975±389 ng/ml for moderate and severe spinal deformities, respectively, when compared to the healthy control group (568±216 ng/ml; n=120). Elevated plasma OPN levels were also found in the asymptomatic at-risk group (871±387 ng/ml; n=87), suggesting that these changes precede scoliosis onset. Data obtained using PBMCs revealed a melatonin signaling impairment only in IS patients at different disease stages when compared to healthy controls showing a high specificity (100%) and sensitivity (100%). Risk of developing a scoliosis in asymptomatic children was determined by CDS in 33% of asymptomatic children at risk.


Both tests have a unique advantage since they can be performed without any prior knowledge of mutations in any defective genes causing AIS. The standard of care for scoliosis has not changed in any significant manner in decades. Patients today are treated in a substantially similar manner to those twenty or thirty years ago – observation, bracing, and fusion as a last resort. Our diagnostic blood-assay may have the potential to change the way scoliosis patients are diagnosed and treated.

Authors’ Affiliations

Sainte-Justine Hospital, Montreal, Canada


© Moreau et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.